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Achieving lasting remissions in patients suffering from
nonlocalized malignancies remains the central problem
of clinical oncology. Although the decades-old arsenal of
classic anticancer treatment modalities such as surgery,
chemotherapy, irradiation, and hormone ablation has
been augmented by strategies including immunothera-
py, gene therapy, inhibition of angiogenesis, hyperther-
mia, and a number of novel lesion-based approaches
such as the administration of the Bcr-Abl kinase
inhibitor STI-571, the goal to eradicate all cancer cells in
a metastasized condition is rarely within reach. Anti-
cancer treatment strategies may be insufficient for many
reasons: potentially efficient therapies might not always
find their way to virtually inaccessible tumor sites. More-
over, the multitude of tumor entities are known to dif-
fer remarkably in their susceptibilities to conventional
DNA-damaging anticancer agents — particularly solid
tumors, which often are largely refractory to chemother-
apy or rapidly re-emerge from a remission. In addition,
primarily susceptible tumors select for genetic defects
during the course of therapy, which may render them
resistant over time. While dose escalation can overcome
the problem of insufficient chemosensitivity in some
entities, its clinical applicability is limited by the severe
toxicity codelivered to the normal cell compartment.
Traditional cytotoxic treatment strategies are driven by
the assumption that quantitative execution of cell death
is required to eliminate the malignant cell population.
Interestingly, strategies to blunt properties of malig-
nant growth by disabling proliferation without prima-
rily targeting cancer viability have been less recognized,
although forcing cells to exit the cell cycle by an irre-
versible arrest should terminate their contribution to
disease progression just as effectively. In fact, recent evi-
dence underscores the theory that premature senes-
cence may act as an acute, drug-inducible arrest pro-
gram that may contribute to the outcome of cancer
therapy (1, 2). In this Perspective, we will review the role
of drug-induced effector programs and discuss to what
extent induction of cellular senescence may be a bene-
ficial result of anticancer therapy.
Anticancer therapy induces programmed 
cellular responses
Chemotherapy remains the mainstay in the treatment
of systemic or metastasized malignancies. Although
these highly toxic agents interfere with a plethora of cel-
lular functions and may damage a variety of cellular
structures, their pivotal cellular target is genomic DNA.
It is now a well-accepted concept that drug-mediated
DNA damage is not invariably lethal per se but provokes
genetically encoded cellular responses. Hence, unrelat-
ed chemotherapeutic anticancer agents — in spite of
their different pharmacological features and their indi-
vidual target molecules participating in DNA replica-
tion and integrity — initiate common downstream
mechanisms. Upon sensing DNA damage, cellular
transducers activate pathways that either temporarily
halt the cell cycle to allow the DNA repair machinery to
fix the damage, or execute lethal programs such as
apoptosis or mitotic catastrophe to restrain the dam-
aged cell from further expansion (see ref. 3 for review).
Ultimate, i.e., irreversible responses to DNA damage do
not always determine the fate of cancer cells by pro-
grammed forms of cell death but may blunt their un-
controlled proliferative capacity by provoking a termi-
nal cell-cycle arrest termed premature senescence (4–6).
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Moreover, recent reports demonstrated that tumor cell
senescence is detectable following DNA-damaging
treatment in vivo and significantly increases overall sur-
vival of the host (1, 2). In turn, the fact that different
anticancer agents share genetic effector cascades renders
the genetically encoded programs of apoptosis and
senescence highly susceptible to inactivating mutations
as a potential cause of chemoresistance. Hence, thor-
ough dissection and mutational analysis of the path-
ways leading to cell death or cellular senescence are
expected to identify specific genetic lesions that may be
utilized by novel targeting therapies.
Drug-inducible senescence is a p53- 
and p16INK4a-controlled program
Premature senescence recapitulates cellular and molec-
ular features of replicative senescence (7), which is a
safeguard program that limits the growth potential,
but not necessarily the viability, of a dividing cell as a
consequence of the progressive shortening of its telom-
eres. Senescent cells, arrested in the G1 phase of the cell
cycle, typically appear flattened and enlarged with
increased cytoplasmic granularity. In addition to the
characteristic morphology, senescent cells display
enhanced activity of senescence-associated β-galactosi-
dase (SA-β-Gal) when assessed at an acidic pH (8, 9).
While refractory to mitogenic stimuli, senescent cells
remain viable and metabolically active and possess a
typical transcriptional profile that distinguishes them
from quiescent cells (10). At the protein level, numer-
ous regulators of cell-cycle progression, checkpoint
control, and cellular integrity such as p53 or p16INK4a
have been found to be induced in response to various
pro-senescent stimuli (4, 11). Although the molecular
mechanisms underlying the senescent phenotype
remain largely unknown, there is increasing evidence
that formation of heterochromatin in the vicinity of
promoters that control gene expression related to cell-
cycle progression might be implicated in the mainte-
nance of an irreversible growth arrest (12).
Extrinsic factors such as anticancer agents, γ-irradia-
tion, or UV light have been shown to induce premature
senescence as a DNA damage–mediated cellular stress
response (4–6). DNA lesions are sensed and transduced
via protein complexes involved in DNA maintenance
and repair, associated with members of the PI3K super-
family that includes the ataxia telangiectasia mutated
kinase (ATM) (13), the ATM-related kinase (ATR), and
DNA-protein kinase, among others (14–18). Besides a
network of other downstream substrates, these kinases
directly or indirectly phosphorylate the gatekeeper of
cellular integrity (19), the p53 protein, at certain
residues. Although a cascade of posttranslational mod-
ifications has been proposed to control p53 activity in
response to DNA damage (20), and different DNA-dam-
aging stimuli such as UV light or γ-irradiation can pro-
duce distinguishable signatures of posttranslational
p53 modifications (21), the actual contribution of dis-
tinct phospho-residues to p53-mediated DNA-damage
responses is still under debate (22, 23). p53 controls a
plethora of effector functions (24), and the precise
mechanisms by which specific downstream pathways
are regulated in response to p53 activation have not
been elucidated yet (25, 26). While it is now clear that
p53 participates not only in apoptosis but also in the
induction of DNA damage–mediated senescence (1, 5,
6), the signals that convert p53 from an apoptosis
executor to a senescence inducer in response to anti-
cancer therapy still need to be identified. Moreover,
the posttranslational p53 modifications found in
cells that entered replicative senescence shared only
partial overlap with p53 modifications typically
induced by DNA damage (27).
Comparable to p53, which functions as a fail-safe
mediator, the cyclin-dependent kinase (CDK) inhibitor
p16INK4a has been implicated in both response to DNA
damage and control of stress-induced senescence (1, 4,
28, 29). Although the molecular mechanism used by
p16INK4a to control not only a temporary but a perma-
nent G1 arrest is largely unclear (30), p16INK4a responds
to DNA damage in a delayed manner and appears to be
indispensable for the maintenance of cellular senes-
cence (1, 2). For example, treatment of normal human
foreskin and lung fibroblasts with DNA-damaging
drugs such as bleomycin or actinomycin D induced an
irreversible cell-cycle arrest with a senescence-like phe-
notype including a transient upregulation of p53 and
p21 protein levels, followed by increased p16INK4a pro-
tein expression and detectable SA-β-Gal activity (4).
Similarly, exposure of adenocarcinoma cells to topoi-
somerase inhibitors produced premature senescence
that was initially accompanied by overexpression of
p53 and p21, whereby the subsequent overexpression
of p16INK4a persisted after drug withdrawal, highlight-
ing the role of p16INK4a in maintenance of the growth
arrest (2). In an in vivo model of drug-senescent mouse
lymphomas, repeated anticancer therapy eventually
selected against senescence-controlling genes such as
the p16INK4a-encoding INK4a alleles or p53 genes, there-
by producing relapse tumors that resumed growth in
an aggressive manner (1). A broader drug screen based
on several tumor cell lines demonstrated inducibility
of a senescence-like arrest in numerous p53-proficient
cancer cell lines in response to doxorubicin and other
DNA-damaging agents, but it also suggested that p53-
independent pathways leading to senescence might
exist when some p53-mutated cell lines were exposed
to escalated doses of doxorubicin (5). Interestingly, not
only DNA-damaging agents, but also compounds that
primarily target microtubules or the differentiating
agent retinoic acid, were found to promote an SA-β-Gal–
positive arrest phenotype. Moreover, a senescence-like
growth arrest was also observed after γ-irradiation of
normal human diploid cells (6, 31). p53 deficiency, pre-
viously reported to disable apoptosis in response to
γ-irradiation (32, 33), also accounted for impaired γ-ir-
radiation–induced senescence in a human carcinoma
cell line wherein senescence could be restored upon
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introduction of wild-type p53 (6). Thus, in a variety of
different test conditions, DNA damage–induced senes-
cence was confirmed as a p53– and p16INK4a–co-con-
trolled safeguard program.
Drug-induced senescence: substitute 
player or powerful reliever?
The possibility of alternative outcomes in response to
drug-induced DNA damage — apoptosis, mitotic catas-
trophe, cellular senescence, or simply necrosis — raises
the question of whether additional stimuli or specific
contextual scenarios determine the ultimate cell fate.
Xenotransplant and transgenic mouse models have
been used to visualize premature senescence as a quan-
titative response to anticancer agents in vivo (1, 5).
Importantly, lymphomas generated in the Eµ-myc
transgenic mouse model were prone to massive apop-
tosis as a default response following therapy with the
alkylating agent cyclophosphamide, but they uni-
formly displayed premature senescence when apopto-
sis was blocked by overexpression of the strictly anti-
apoptotic mediator Bcl2 (1). Although mice harboring
senescent lymphomas ultimately succumbed to their
disease, they lived much longer than those bearing
lymphomas with a defect in both apoptosis and senes-
cence as a consequence of p53 loss. Given the rapid
induction of apoptosis and the rather delayed
detectability of an SA-β-Gal–positive long-term arrest
in response to anticancer therapy in vivo, the data sug-
gested that the senescence machinery may act as a
back-up program to substitute for or to reinforce an
insufficient apoptotic response (34). The actual
impact of a fictitious population of cells that chose to
primarily enter senescence is difficult to assess, since
apoptotically competent tumors typically regress to a
remission with no apparent residual tumor mass left.
Senescent cells have also been detected in archival
tumor samples from breast cancer patients who
underwent neoadjuvant chemotherapy prior to surgi-
cal removal of their tumors. In contrast to untreated
tumor samples, these samples revealed significant pos-
itive staining for SA-β-Gal activity associated with
high expression of p16INK4a (2). Hence, intrinsically
rather chemosensitive entities such as hematological
malignancies may use senescence as a secondary mech-
anism, while typically less susceptible solid tumors
might rely on premature senescence as the chief drug-
response program available.
According to many naturally occurring mutations in
apoptosis-related genes, disruption of apoptosis is, at
least in conjunction with certain oncogenic scenarios,
a pivotal step in tumor development. Given the com-
plex overlap between apoptosis and senescence as cel-
lular fail-safe systems on one hand and tumor-sup-
pressor mechanisms and drug-effector programs on
the other hand, the capability to execute senescence
might be disabled in cancer cells for numerous reasons.
In fact, mutations in genes that control cellular senes-
cence may not only be selected for during therapy but
might have been acquired already during tumor devel-
opment (1). Oncogenes such as activated ras that are
known to provoke premature senescence as the pri-
mary fail-safe mechanism may rely on defects in this
program as a prerequisite to a fully transformed phe-
notype (28, 35), possibly inactivating senescence as a
drug response as well. Nevertheless, tumors that pre-
serve both an intact apoptotic and a functional senes-
cence program may display a particularly robust drug
response consisting of acutely inducible cell death in
a first phase, corroborated by delayed apoptosis out
of senescence at a later point (Figure 1). Although
apoptosis is a fast-acting response mode, little is
known about the possibility that apoptosis-compe-
tent cells might be sent into senescence following
DNA-damaging therapy — and whether a senescent
tumor could ever undergo apoptosis upon an addi-
tional proapoptotic signal (36). Finally, senescence
could be recruited as an amplifier mechanism to lock
temporarily arrested tumor cells — with their reduced
susceptibility to checkpoint-licensed apoptosis — into
irreversible cytostasis.
No effect without side effects
The fate of apoptotic cells is determined by their acute
disruption of metabolic processes, rapid disintegra-
tion, and engulfment by attracted macrophages. In
stark contrast, induction of cellular senescence as a
formally irreversible growth arrest results in the preser-
vation of a potentially malignant cell population
locked into a nondividing state, yet possessing at least
some metabolic activity (8). Although apoptotic cells
provoke rather little inflammatory reaction, tumor-
infiltrating immune cells reportedly can recognize
altered autoantigens presented by apoptotic cancer
cells (37). To what extent altered senescent tumor cells
that previously managed to escape immunosurveil-
lance can now challenge an antitumor immune
response requires further investigation (Figure 1). Cor-
relative evidence points toward a link between dermal
autoimmunity in the elder population and an age-
dependent increase of SA-β-Gal–positive keratinocytes
in human skin samples (8).
Although it is likely that senescent cells will ulti-
mately be cleared by phagocytosis, no “eat-me” signals,
as recently described for apoptotic cells, have been iden-
tified yet for the senescent state (38). While senescent
neutrophils, like apoptotic granulocytes (39), might
ultimately face phagocytosis through a yet unknown
recognition mechanism (40), focal enrichment of lyso-
some-related β-galactosidase activity at autodigestive
vacuoles indicated that aged human fibroblasts arrest-
ed in replicative senescence may eventually eliminate
themselves by autophagy (41). As a side effect of anti-
cancer therapy, DNA damage can also force susceptible
normal cells to enter an acute SA-β-Gal–positive arrest
in vivo (S. Lee and C.A. Schmitt, unpublished observa-
tions). Hence, it is conceivable that senescent cancer
and normal bystander cells reside for some time next to
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their non-senescent malignant neighbors. In line with
the role of irradiated fibroblasts as feeder cells, and
with evidence reported by Waldman and colleagues,
who described improved clonogenic growth in the pres-
ence of irradiation-arrested bystander cells (42), inter-
spersed senescent — i.e., metabolically active — cells
may support survival and growth of tumor cells in their
vicinity. Campisi and coworkers demonstrated that
senescent human fibroblasts stimulated proliferation
of epithelial cell lines in vitro (43). Moreover, coim-
plantation of senescent fibroblasts together with pre-
neoplastic epithelial cells in nude mice accelerated
tumor formation in vivo, mainly via soluble factors
secreted by the senescence-activated fibroblasts. Thus,
the outcome of anticancer therapy is not only deter-
mined by a quantitative effect on cancer cells forced to
irreversibly exit the cell cycle but may also depend on
novel capabilities acquired by senescent cells that can
impact their malignant neighbors in different ways
(Figure 1). It is quite possible that, because of func-
tionally compromised cell-cell interactions, senescent
tumor cells can even exert a tumor-suppressive effect
on their bystander cells.
Rest in peace?
Cellular senescence has become an attractive therapeu-
tic concept because it qualitatively equals programmed
cell death by excluding cells from active progression
through the cell cycle. However, its therapeutic poten-
tial strongly relies on the irreversibility of this process.
Unlike apoptosis, which acutely eliminates a potential-
ly harmful cell, cellular senescence represents an oper-
ational change in a still-viable cell. Any cellular switch
that could revert senescent cells into dividing cells
implies the threat of a tumor relapse — at least as long
as senescent cells have not been cleared by other
processes such as phagocytosis. In fact, several experi-
ments have provided evidence that senescence is a for-
mally reversible process if proteins involved in its main-
tenance are lost. For example, reversal of replicative
senescence in human lung fibroblasts was achieved via
functional inactivation of both p53 and the retinoblas-
toma protein (pRB) by the expression of simian virus
40 large T antigen protein, or, as an alternative, by a
combination of p53 inactivation and knockdown of
p16INK4a expression using small interfering RNA
(siRNA) molecules (44). In contrast, the mere suppres-
sion of p53 function proved already sufficient to revert
the senescent phenotype of human foreskin fibroblasts
(44). Likewise, siRNA-driven inactivation of p53 in
mouse embryonic fibroblasts (MEFs) enabled the cells
to resume proliferation out of replicative senescence
(45). These findings are in accordance with the putative
cooperativity of p53 and p16INK4a — and possibly pRB —
in the induction and maintenance of premature senes-
cence in vivo (1). Accordingly, the acute inactivation of
pRB via recombinase-mediated gene deletion in MEFs
that entered senescence upon replicative exhaustion or
in response to oncogenic ras allowed the cells to re-
emerge from the arrested phenotype (46). However, it
needs to be shown that this cell-cycle re-entry truly
reflects restored proliferative capacity and will not sim-
ply promote cell death by apoptosis or mitotic catas-
trophe within a few additional divisions.
Importantly, these experimental scenarios have not
formally tested whether drug-inducible senescence is
a reversible process as well. In the p53- and pRB-defi-
cient cell line Saos-2, premature senescence — in addi-
tion to substantial cell death — was observed in
response to doxorubicin treatment, suggesting a p53-
Figure 1
Drug-inducible senescence: friend or foe? In response to
DNA-damaging agents, cancer cells can rapidly undergo
apoptosis or may enter premature senescence as a potential
back-up mechanism. Whether cells re-enter the cycle or exe-
cute apoptosis out of drug-mediated senescence remains
unclear. A terminal arrest of the entire cancer cell popula-
tion, possibly augmented through increased immunogenic-
ity of senescent cells, is beneficial for the host. In contrast,
feeder-like growth that reflects paracrine activity of senes-
cent cells on their non-senescent neighbors, or escape from
senescence based on acquired or preexisting mutations, is
considered a detrimental outcome.
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and pRB-independent pathway to senescence (5). Fur-
thermore, overexpression of a temperature-sensitive
pRB transgene in Saos-2 cells produced a senescent
phenotype. As a result of transgene inactivation, reini-
tiation of DNA synthesis was observed, and the cells
underwent apoptotic cell death via the p53 homologue
p73, indicating that active pRB is required to maintain
the senescent state of these cells (47). This somewhat
artificial setting underscores the complex wiring of sig-
naling pathways into senescence, their relative respon-
siveness to different stimuli, their dependency on the
cell type, and their sensitivity to experimental ap-
proaches based on nonphysiological overexpression of
candidate regulators. Nevertheless, some of the exper-
iments demonstrating successful reversal of cellular
senescence that senescent cancer cells could actually
encounter in vivo. While the acquisition of sponta-
neous mutations that disable p53 or pRB in a resting
cell without DNA replication seems rather unlikely,
epigenetic changes, for example, promoter methyla-
tion to silence p16INK4a expression, might occur in
senescent cells (Figure 1).
Exploiting cellular senescence for cancer therapy
The uncertainties regarding control and irreversibility of
drug-induced senescence raise concerns as to what
extent this effector mechanism reflects a desirable out-
come of cancer therapy, particularly in light of therapy-
inducible apoptosis as the alternate and possibly safer
outcome in response to DNA damage. However, an
intact apoptotic machinery is often unavailable in estab-
lished malignancies. Since anticancer agents kill mainly
by apoptotic cell death and, in turn, achieve little clinical
efficacy in the presence of apoptotic defects (see, for
example, refs. 48–52), promising treatment alternatives
must use effector mechanisms that do not rely on an
intact apoptotic machinery. Importantly, in vivo analy-
ses of treatment responses in primary lymphomas har-
boring defined genetic lesions demonstrated that induc-
tion of senescence despite the presence of an apoptotic
block improved the outcome of anticancer therapy (1) —
regardless of a potential reversal or possible emergence
of preexisting escape mutants at a later time.
Appropriate test systems are critical to elucidate the
complex implications of drug-inducible senescence. Not
surprisingly, drug sensitivity assays performed on pri-
mary tumor material in culture unveiled that adaptation
to the nonphysiological culture conditions selected for
apoptotic defects and chemoresistance (50). Paradoxi-
cally, many cell lines retain the ability to enter senescence
following drug exposure in vitro (5), although inactiva-
tion of the terminal-arrest program appears to be a key
prerequisite for any primary tumor during successful
establishment as a continuous cell line. Irrespective of
the technical inducibility of a senescence-like phenotype
in culture-adapted cells, a Petri dish setting cannot
mimic the complexity and interactivity of a natural
tumor environment in vivo. Hence, many of the ques-
tions raised about the role of drug-induced senescence
need to be addressed in vivo using physiological model
systems. Tractable mouse models of cancer, such as the
transgenic Eµ-myc lymphoma model (1), in alliance with
sophisticated genetic tools will allow researchers to dis-
sect the pathways and the impact of drug-inducible
senescence in vivo. Moreover, large-scale analyses of the
transcriptome and proteome of primary human tumor
samples will expand our understanding of the molecu-
lar mechanisms that underlie drug responses in sensitive
and resistant conditions.
Given the impact of apoptotic defects on tumor biol-
ogy and treatment outcome, it is a research priority to
invent small compound– or gene therapy–based
approaches that may resensitize cancer cells to death
signals. Likewise, one can envision lesion-based strate-
gies to restore a defective senescence response. Ulti-
mately, direct activation of pro-senescent pathways
without induction of deleterious DNA damage seems
to be a particularly appealing concept. For instance,
cDNA microarray analysis of human diploid fibrob-
lasts revealed that cGMP synthesis was inhibited dur-
ing replicative senescence. Exposure of tumor cells to
a guanylate cyclase inhibitor induced, by activation of
the CDK inhibitor p21, a senescent phenotype that
was independent of its upstream regulator p53, indi-
cating that induction of p21 activity might be suffi-
cient to halt cell proliferation, even in the absence of
functional p53 and without an additional DNA-dam-
age signal (53). Furthermore, a synthetic inhibitor of
CDK4 — possibly mimicking the role of p16INK4a to
maintain a senescent phenotype — also produced a
DNA damage–independent form of premature senes-
cence in cells lacking proper p16INK4a expression and
inhibited the growth of xenotransplant tumors in
mice (54). Inactivation of the papilloma virus onco-
proteins E6 and E7, which deregulate the p53 and Rb
proteins, respectively, by siRNA molecules restored cel-
lular senescence in cervical cancer cells (55).
Cellular senescence and its potential use as a drug-
effector program remains a complex biological phe-
nomenon with unknown significance in cancer thera-
py. Whether cellular senescence is rather friend or foe
most likely depends on accompanying lesions, first of
all in apoptotic response programs, and on the cellu-
lar context. In further preclinical investigations, it will
be of particular interest to explore therapies that do
not deliver devastating DNA damage to the cell, that
do not rely on functional DNA-damage transducer
systems, and that do not target pathways already
mutated to cancel apoptosis, but that directly prompt
a senescence response.
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